Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily single-strength vs thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients
TCTR20240329004Phase 4Completed
- Sponsor
- N/A
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trimethoprim + sulfamethoxazole in pneumocystis pneumonia (PCP), sponsored by N/A. Started Dec 2022; status: completed.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on TCTR20240329004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240329004.